Metal Chelators as Anticancer Approach: Part I; Novel 7-Anisidine Derivatives with Multidentate at 7-8 Carbons of Fluoroquinolone Scaffold as Potential Chelator Anticancer and Antilipolytic Candidates
DOI:
https://doi.org/10.35516/jjps.v16i2.1467Keywords:
Metal chelators, Multidentate, Fluoroquinolones, Chelator anticancerAbstract
Background: Cancer is one of the greatest troubling maladies currently. It is believed that it is the second reason for death following cardiovascular maladies. Owing to the multiplicity of its types, stages and genetic basis, there is no existing drug to cure all types of cancer. Resistance to present drugs and severe adverse effects are other challenges in the struggle against cancer. In such pursuit, fluoroquinolones (FQs) have the potential as antiproliferative compounds due to safety, low cost, and absence of resistance.
Aims: In this study, we aim to synthesize biologically active compounds that have dual anticancer and anti-lipase potential. Sixteen compounds were prepared, fully characterized, and studied through identification of IC50 values against the highly susceptible cancer cell lines.
Methods: In this work we are concerned with synthesizing biologically active compounds that belong to fluoroquinolones (FQs) with dual anti-colorectal cancer and anti-lipase activity, owing to association between cancer and obesity, conduct titration and docking experiments to validate our hypothesis.
Results: In vitro findings indicated that these compounds demonstrated promising anticancer activity against tested cell lines in micromolar range with a potency comparable to cisplatin. Compound 11 exhibited approximately doubled potency compared to cisplatin against SW620 colorectal cancer cell line with IC50 3.2 μM which proposes FQs as potent antiproliferative agents. The synthesized Fluoroquinolone (FQ) compounds were further screened for their in vitro anti-lipase potential. The findings demonstrated that all the screened compounds have demonstrated remarkable anti-lipase activity, as compared to control molecule orlistat. Compound 9 exhibited comparable activity to orlistat against pancreatic lipase with IC50 0.4 μM which proposes FQs as potent pancreatic lipase inhibitors.
Conclusions: The anticancer potential of these derivatives is referred to their ability to inhibit Topo II which indicates that chelation is the mechanism of inhibition of Topo II emphasized with titration and docking experiments.
References
(1) Appelbaum, P. C. & Hunter, P. A. The fluoroquinolone antibacterials: past, present and future perspectives. International Journal of Antimicrobial Agents, 2000; 16 (1), 5-15.
(2) Edmont, D. S., Rocher, R., Plisson, C. et al.Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorganic & Medicinal Chemistry Letters, 2000; 10 (16), 1831-1834.
(3) Zhao, Y.-L., Chen, Y.-L., Sheu, J.-Y.et al.Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. Bioorganic & Medicinal Chemistry, 2005; 13 (12), 3921-3926
(4) Lucero, B. D. A., Gomes, C. R. B., Frugulhetti, I. C. D. P. P. et al. Synthesis and anti-HSV-1 activity of quinolonic acyclovir analogues. Bioorganic & Medicinal Chemistry Letters, 2006; 16 (4), 1010-1013.
(5) Shaharyar, M., Ali, M. A. & Abdullah, M. M. Synthesis and antiproliferative activity of 1-[(sub)]-6-fluoro-3-[(sub)]-1, 3, 4-oxadiazol-2-yl-7-piperazino-1, 4-dihydro-4-quinolinone derivatives. Medicinal Chemistry Research, 2007; 16 (6), 292-299.
(6) Al-Hiari, Y. M., Kasabri, V. N., Shakya, A. K. et al. Fluoroquinolones: novel class of gastrointestinal dietary lipid digestion and absorption inhibitors. Medicinal Chemistry Research, 2014a; 23 (7), 1-11.
(7) Sissi, C. & Palumbo, M. The quinolone family: from antibacterial to anticancer agents. Current Medicinal Chemistry-Anti-Cancer Agents, 2003; 3 (6), 439-450.
(8) Kloskowski, T., Gurtowska, N., Nowak, M.et al. The influence of ciprofloxacin on viability of A549, HepG2, A375. S2, B16 and C6 cell lines in vitro. Acta Poloniae Pharmceutica, 2011; 68 859-865.
(9) Azema, J. L., Guidetti, B., Dewelle, J.et al. 7-((4-Substituted) piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorganic & Medicinal Chemistry, 2009; 17 (15), 5396-5407.
(10) Kumar, A. R., Lingaiah, B. P. V., Rao, P. S.et al.. Synthesis and biological evaluation of novel N1-decyl and C7-sec amine substituted fluoroquinolones as antitubercular and anticancer agents. Indian Journal of Chemistry, 2015; 54 1495-1501.
(11) Al-Trawneh, S. A., Zahra, J. A., Kamal, M. R.et al. Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents. Bioorganic & Medicinal Chemistry, 2010; 18 (16), 5873-5884.
(12) Abbas, J. A. & Stuart, R. K. Vosaroxin: a novel antineoplastic quinolone. Expert Opinion on Investigational Drugs, 2012; 21 (8), 1223-1233.
(13) Hawtin, R. E., Stockett, D. E., Byl, J. A. W.et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One, 2010; 5 (4), e10186.
(14) Sweidan K, Sabbah DA, Bardaweel S, et al. Facile synthesis, characterization, and cytotoxicity study of new 3-(indol-2-yl) bicyclotetrazatridecahexaens. Can J Chem 2017; 95(8):858-862.
(15) Al-Hiari, Y. M., Abu-Dahab, R. & El-Abadelah, M. M. Heterocycles [h]-Fused Onto 4-Oxoquinoline-3-Carboxylic Acid, Part VIII [1]. Convenient Synthesis and Antimicrobial Properties of Substituted Hexahydro [1, 4] diazepino [2, 3-h] quinoline-9-carboxylic acid and Its Tetrahydroquino [7, 8-b] benzodiazepine Analog. Molecules, 2008; 13 (11), 2880-2893.
(16) Al-Hiari, Y. M., Shakya, A. K., Alzweiri, M. H. Synthesis and biological evaluation of substituted tetrahydro-1h-quino [7, 8-b][1, 4] benzodiazepine-3-carboxylic derivatives. FARMACIA, 2014b; 62 (3), 570-588.
(17) Winkler, F. K., D'arcy, A. & Hunziker, W. Structure of human pancreatic lipase. Nature, 1990; 343 (6260), 771-774.
(18) Lowe, M. E. Structure and function of pancreatic lipase and colipase. Annual Review of Nutrition, 1997; 17 (1), 141-158.
(19) Birari, R. B. & Bhutani, K. K. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discovery Today, 2007; 12 (19), 879-889.
(20) Vichai, V., and Kirtikara, K. Sulforhadamine B colorimetric assay for cytotoxicity screening. Nature Protocols, 2006; 1, 1112-1116.
(21) Kasabri, V., Afifi, F. U., Abu-Dahab, R. In vitro modulation of metabolic syndrome enzymes and proliferation of obesity-related-colorectal cancer cell line panel by Salvia species from Jordan. Revue Roumaine de Chimie, 2014; 59 693-705.
(22) Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer, 2009; 9(5), 338-350.
(23) Molinspiration server (www.molinspiration.com): Molinspiration property engine v2021.10
(24) MarvinSketch16.10.24 ChemAxon - Software Solutions and Services for Chemistry & Biology 2016.
(25) OMEGA, O. 2.5. 1.4: OpenEye Scientific Software, Santa Fe, NM. Google Scholar There is no corresponding record for this reference.
(26) Wu, C. C., Li, T. K., Farh, L.et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science, 2011; 333(6041), 459-462.
(27) OEDOCKING 3.2.0.2: Open Eye Scientific Software, Santa Fe, NM. http://www.eyesopen.com
(28) BIOVIA, Dassault Systemes, BIOVIA Discovery Studio Visualizer, v17.2.0.16349, San Diego: Dassault systems, 2016.
(29) Mitscher, L. A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chemical Reviews, 2005; 105 (2), 559-592.
(30) Al-Hiari, Y. M., Qaisia, A. M., Shuheil, M. Y. A.et al. Synthesis and Antibacterial Potency of 4-Methyl-2, 7-dioxo-1, 2, 3, 4, 7, 10-hexahydropyrido [2, 3-f] quinoxaline-8-carboxylic acid, Selected [a]-Fused Heterocycles and Acyclic Precursors. Zeitschrift fuer Naturforschung B: Chemical Sciences, 2007b ; 62 (11), 1453-1458.
(31) Al-Hiari, Y. M., Qandil, A. M., Al-Zoubi, R. M.et al. (2010), 7-(3-Chlorophenylamino)-1-cyclopropyl-6-fluoro-8-nitro-4-oxo-1, 4-dihydroquinoline-3-carboxylic Acid. Molbank, 2010 (2), M669.
(32) Arabiyat, S., Kasabri, V., Al‐Hiari, Y.et al. Antilipase and antiproliferative activities of novel fluoroquinolones and triazolofluoroquinolones. Chemical Biology & Drug Design, 2017; 90(6), 1282-1294.
(33) World Cancer Research, F. & American Institute for Cancer, R. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. American Institution for Cancer Research, 2007.
(34) Kathiravan, M. K., Khilare, M. M., Nikoomanesh, K.et al. Topoisomerase as target for antibacterial and anticancer drug discovery. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013; 28 (3), 419-435.
(35) Arabiyat, S., Kasabri, V., & Al-Hiari, Y. Antilipolytic-Antiproliferative Activity of Novel Antidiabesity Triazolo/Fluoroquinolones. Jordan J. of Pharm. Scie., 2020; 13(1).
(36) Khaleel, S., Al-Hiari, Y., Kasabri, V.et al. Antiproliferative Properties of 7, 8-Ethylene Diamine Chelator-Lipophilic Fluoroquinolone Derivatives Against Colorectal Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2022; 22(5), 1012-102835.
(37) Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26
(38) Veber DF, Johnson SR, Cheng HY.et al.Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23.
(39) Nath, A., Kumer, A., Zaben, F.et al. Investigating the binding affinity, molecular dynamics, and ADMET properties of 2, 3-dihydrobenzofuran derivatives as an inhibitor of fungi, bacteria, and virus protein. Beni-Suef University Journal of Basic and Applied Sciences, 2021; 10(1), 1-13.
(40) Arabiyat, S., Kasabri, V., Al-Hiari, Y.et al. Dual glycation-inflammation modulation, DPP-IV and pancraetic lipase inhibitory potentials and antiproliferative activity of novel fluoroquinolones. Asian Pacific journal of cancer prevention: APJCP, 2019; 20(8), 2503.
(41) Bentley, D., Young, A.-M., Rowell, L.et al. Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat. Journal of Cardiovascular Pharmacology, 2012; 60 (4), 390-396.
(42) Habtemariam, S. The anti-obesity potential of sigmoidin A. Pharmaceutical Biology, 2012; 50 (12), 1519-1522.
(43) Arabiyat, S., Al-Hiari, Y., Bustanji, Y.et al. In Vitro modulation of pancreatic lipase and proliferation of obesity related colorectal cancer cell line panel by novel synthetic triazoloquinolones. Rev. Roum. Chim, 2016; 61(11-12), 871-879.
(44) Al-Hiari, Y., Sweileh, B., Shakya, A.et al. Synthesis of 1-Benzyl-1, 2, 3, 4-Tetrahydroisoquinoline, Part I: Grignard Synthesis of 1-(Substitutedbenzyl)-1,2,3,4-Tetrahydroisoquinoline Models with Potential Antibacterial Activity, Jordan J. of Pharm. Sci., 2009; 2(1), 1-21, 2009.
